Bronchial asthma is a common chronic inflammatory disease affecting the airway. Cytokines have a pivotal role in regulation of the immune response, and in development of asthma. Interleukin 33 is a newly discovered member of cytokines, belongs to interleukin 1 family. Previous studies have reported that expression of IL33 is associated with bronchial asthma. This study aimed to evaluate the prevalence of interleukin 33 (IL33) single nucleotide polymorphism (SNP) rs1929992 in asthmatic patients and determine the relation of IL33SNP to IL33 serum level. The Results of RFLP were validated by using sterile distilled water. This study included 100 patients from Egypt, Beni Suef governorate (Upper Egypt) and Mansoura governorate (Delta region), complaining of chronic asthma and 100 control subjects with matched sex and residence. Blood samples from study subjects were used for determination of serum IL33by ELISA and IL33 SNP rs1929992 by PCR-RFLP. There was no significant difference between the proportions of IL33 SNP rs1929992 genotypes in asthma patients and the control group. Allele ‘A’ predominates in asthmatics though this did not achieve statistical significance (P=0.071). IL33 level was compared in the three IL33 SNP rs1929992 genotypes; G/G, G/A, and A/A, and it revealed no significant difference (P = 0.958). The association between IL33 with asthma showed that the log-additive model is the best inheritance model which marks allele ‘A’ as the risk allele. In contrast, IL33 serum level was significantly higher in severe asthma than the moderate asthma and the mild type (P<0.0005). Spearman’s correlation test showed that IL33 level rises as asthma severity increases (rs=0.880, P<0.0005). In conclusion our data revealed no evidence that SNP of IL33 rs1929992 may contribute to the development of asthma in Egyptian population. However, there is a strong positive correlation between IL33 serum level and asthma severity.

Background Carbapenem-resistant Gram-negative organisms (CRGNO) are a growing threat. We aimed in our study to determine the genotype of carbapenemases at Beni-Suef University Hospital by using newly introduced lateral flow assays in comparison with molecular techniques and test the effectiveness of ceftazidime/avibactam against them. Methods Screening for carbapenemase production was done by mSuperCARBA (CHROMagar™ company). Genotypic characterization was done using 3 different kits of lateral flow assays: the NG-Test CARBA5 assay (NG Biotech, Guipry, France), RESIST-3 O.K.N. (Coris BioConcept, Belgium) and Carbapenem-resistant K.N.I.V.O Detection K-Set (Beijing Gold Mountain river Tech Development Co, China), whereas genotypic characterization was done for blaVIM blaIMP, blaKPC, blaOXA-48, and blaNDM by PCR. Results The high prevalence of CRGNO in Beni-Suef University Hospital (29%) was dominated by Klebsiella pneumonia (83.3%) harboring OXA-48 (92%). Lateral flow immunoassays showed high sensitivity and specificity for each type of carbapenemases in comparison with PCR. Conclusion The coexistence of multiple carbapenemases genes in the same isolate increased resistance to new therapeutic options, e.g., CZA/AVI. Proper implementation of isolation measures in health care facilities can render the spread of CRGNO.

No abstract